Literature DB >> 8212307

Humanized antibodies.

G Winter1, W J Harris.   

Abstract

Hybridoma technology enabled rodent monoclonal antibodies to be created against human pathogens and cells, but these had limited clinical utility. Protein engineering, reviewed her by Greg Winter and William Harris, is now generating antibodies for treatment of infectious disease, autoimmune disease and cancer by 'humanizing' rodent antibodies. Humanized antibodies have improved pharmacokinetics, reduced immunogenicity and have been used to clinical advantage.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8212307     DOI： 10.1016/0165-6147(93)90197-r

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  10 in total

1.  Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis.

Authors:  Jim Hill; Catherine Copse; Sophie Leary; Anthony J Stagg; E Diane Williamson; Richard W Titball
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

2.  A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin.

Authors:  D Castelletti; G Fracasso; S Righetti; G Tridente; R Schnell; A Engert; M Colombatti
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

3.  Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach.

Authors:  Andreas Lehmann; Josephine H F Wixted; Maxim V Shapovalov; Heinrich Roder; Roland L Dunbrack; Matthew K Robinson
Journal:  MAbs       Date:  2015-09-04       Impact factor: 5.857

4.  Evolution of highly active enzymes by homology-independent recombination.

Authors:  Karl E Griswold; Yasuaki Kawarasaki; Nada Ghoneim; Stephen J Benkovic; Brent L Iverson; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-11       Impact factor: 11.205

Review 5.  Antibodies as carrier proteins.

Authors:  B N Rehlaender; M J Cho
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

6.  A divide-and-conquer approach to determine the Pareto frontier for optimization of protein engineering experiments.

Authors:  Lu He; Alan M Friedman; Chris Bailey-Kellogg
Journal:  Proteins       Date:  2011-12-16

7.  Generation of high-affinity fully human anti-interleukin-8 antibodies from its cDNA by two-hybrid screening and affinity maturation in yeast.

Authors:  Ling Ding; Mark Azam; Yu-Huei Lin; James Sheridan; Shuanghong Wei; Gigi Gupta; Rakesh K Singh; Michelle H Pauling; Waihei Chu; Antares Tran; Nai-Xuan Yu; Jiefeng Hu; Wei Wang; Hao Long; Dong Xiang; Li Zhu; Shao-Bing Hua
Journal:  Protein Sci       Date:  2010-10       Impact factor: 6.725

8.  Optimization algorithms for functional deimmunization of therapeutic proteins.

Authors:  Andrew S Parker; Wei Zheng; Karl E Griswold; Chris Bailey-Kellogg
Journal:  BMC Bioinformatics       Date:  2010-04-09       Impact factor: 3.169

9.  Mechanistic principles of an ultra-long bovine CDR reveal strategies for antibody design.

Authors:  Hristo L Svilenov; Julia Sacherl; Ulrike Protzer; Martin Zacharias; Johannes Buchner
Journal:  Nat Commun       Date:  2021-11-18       Impact factor: 14.919

Review 10.  Development of CAR T Cell Therapy in Children-A Comprehensive Overview.

Authors:  Michael Boettcher; Alexander Joechner; Ziduo Li; Sile Fiona Yang; Patrick Schlegel
Journal:  J Clin Med       Date:  2022-04-12       Impact factor: 4.964
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.